Windtree Therapeutics (WINT) Price & Analysis

Q: What was Windtree Therapeutics’s price range in the past 12 months?

Windtree Therapeutics lowest stock price was $0.06 and its highest was $31.85 in the past 12 months.

Q: What is Windtree Therapeutics’s market cap?

Windtree Therapeutics’s market cap is $2.77M.

Q: When is Windtree Therapeutics’s upcoming earnings report date?

Windtree Therapeutics’s upcoming earnings report date is Apr 08, 2026 which is in 150 days.

Q: Is Windtree Therapeutics overvalued?

According to Wall Street analysts Windtree Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Windtree Therapeutics pay dividends?

Windtree Therapeutics does not currently pay dividends.

Q: What is Windtree Therapeutics’s EPS estimate?

Windtree Therapeutics’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Windtree Therapeutics have?

Windtree Therapeutics has 33,634,220 shares outstanding.

Q: Which hedge fund is a major shareholder of Windtree Therapeutics?

Among the largest hedge funds holding Windtree Therapeutics’s share is Deerfield Management Company, LP. It holds Windtree Therapeutics’s shares valued at 0.

Compare

390 Followers

WINT Stock Chart & Stats

$0.07

-$0.02(-5.33%)

At close: Jan 08 4:00 PM EST

$0.07

-$0.02(-5.33%)

Day’s Range― - ―

52-Week Range$0.06 - $31.85

Previous CloseN/A

Volume14.98M

Average Volume (3M)403.29K

Market Cap

$2.77M

Enterprise Value$14.15M

Total Cash (Recent Filing)$301.00K

Total Debt (Recent Filing)$8.69M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Apr 08, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding33,634,220

10 Day Avg. Volume496,404

30 Day Avg. Volume403,289

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.09

Price to Sales (P/S)0.00

P/FCF Ratio-0.06

Enterprise Value/Market Cap5.10

Enterprise Value/Revenue157.25

Enterprise Value/Gross Profit-122.00

Enterprise Value/Ebitda-0.97

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Windtree Therapeutics News

Windtree Therapeutics Issues Convertible Notes for Settlement

Windtree Therapeutics ( ($WINT) ) just unveiled an announcement. On October 9, 2025, Windtree Therapeutics issued $1.6 million...

23d ago

WINT

Windtree Therapeutics CMO Steven Simonson Resigns

The latest update is out from Windtree Therapeutics ( ($WINT) ). On September 2, 2025, Steven G. Simonson,...

2M ago

WINT

Windtree Therapeutics Approves Key Financial Structure Changes

Windtree Therapeutics ( ($WINT) ) has shared an update. On August 28, 2025, Windtree Therapeutics held a virtual...

2M ago

WINT

Windtree Therapeutics stockholders approve key proposals

Windtree Therapeutics (WINT) announced that key proposals for its corporate strategy were approved at the Special Stockholder Meeting...

2M ago

WINT

Windtree Therapeutics Faces Nasdaq Delisting Notice

The latest update is out from Windtree Therapeutics ( ($WINT) ). On August 19, 2025, Windtree Therapeutics Inc....

3M ago

WINT

Windtree Therapeutics Delays Q2 2025 Report Filing

Windtree Therapeutics ( ($WINT) ) has released a notification of late filing. Windtree Therapeutics, Inc. has announced a...

3M ago

WINT

Windtree Therapeutics announces istaroxime chosen for presentation at HFSA

Windtree Therapeutics (WINT) announced that istaroxime was chosen for a presentation entitled, “Safety and Efficacy of intravenous administration...

3M ago

WINT

Windtree Therapeutics Terminates SEISMiC-C Clinical Study

Windtree Therapeutics ( ($WINT) ) has shared an announcement. Windtree Therapeutics, Inc. has decided to terminate its SEISMiC-C...

3M ago

WINT

Windtree Therapeutics Reveals Promising Phase 2 Study Data

Windtree Therapeutics ( ($WINT) ) has issued an announcement. On August 5, 2025, Windtree Therapeutics announced interim data...

3M ago

WINT

Windtree announces results of interim analysis of SEISMiC Phase 2 study

Windtree Therapeutics (WINT) has performed a planned interim analysis of the SEISMiC C Phase 2 study data evaluating...

3M ago

WINT

Windtree Therapeutics Appoints New Audit Committee Chair

The latest announcement is out from Windtree Therapeutics ( ($WINT) ). On July 29, 2025, Windtree Therapeutics, Inc....

3M ago

WINT

Windtree Therapeutics announces reduction of Preferred Series C, D shares

Windtree Therapeutics (WINT) announced large reductions in outstanding shares of its preferred series C and D shares. Only...

3M ago

WINT

Windtree Therapeutics Secures $500M Equity Line for Crypto

An announcement from Windtree Therapeutics ( ($WINT) ) is now available. On July 23, 2025, Windtree Therapeutics entered...

4M ago

WINT

Windtree enters into common stock purchase agreement for up to $500M

Windtree Therapeutics (WINT) announced it has entered into a Common Stock Purchase Agreement for up to $500M to...

4M ago

WINT

WINT FAQ

What was Windtree Therapeutics’s price range in the past 12 months?

Windtree Therapeutics lowest stock price was $0.06 and its highest was $31.85 in the past 12 months.

What is Windtree Therapeutics’s market cap?

Windtree Therapeutics’s market cap is $2.77M.

When is Windtree Therapeutics’s upcoming earnings report date?

Windtree Therapeutics’s upcoming earnings report date is Apr 08, 2026 which is in 150 days.

How were Windtree Therapeutics’s earnings last quarter?

Currently, no data Available

Is Windtree Therapeutics overvalued?

According to Wall Street analysts Windtree Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Windtree Therapeutics pay dividends?

Windtree Therapeutics does not currently pay dividends.

What is Windtree Therapeutics’s EPS estimate?

Windtree Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Windtree Therapeutics have?

Windtree Therapeutics has 33,634,220 shares outstanding.

What happened to Windtree Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Windtree Therapeutics?

Among the largest hedge funds holding Windtree Therapeutics’s share is Deerfield Management Company, LP. It holds Windtree Therapeutics’s shares valued at 0.

Company Description

Windtree Therapeutics

Windtree Therapeutics, Inc. (WINT) is a biotechnology company focused on developing novel therapeutics for patients suffering from acute pulmonary disorders. The company primarily operates within the biopharmaceutical and healthcare sectors. Windtree's lead product candidates are designed to address significant unmet medical needs in areas such as respiratory distress syndrome (RDS) in premature infants and acute respiratory failure in adults. The company leverages its proprietary KL4 surfactant technology and other innovative therapeutic approaches to enhance patient outcomes.